ARTV Stock Risk & Deep Value Analysis
Artiva Biotherapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on ARTV
We analyzed Artiva Biotherapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ARTV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
ARTV Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Artiva Biotherapeutics Inc (ARTV)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$102.60M
ARTV Deep Value Analysis
Compare ARTV to Similar Stocks
See how Artiva Biotherapeutics Inc stacks up against related companies in our head-to-head analysis.
ARTV Red Flags & Warning Signs
- âš
Failure to secure adequate financing, leading to further dilution or operational shutdown
- âš
Negative or inconclusive clinical trial results for AB-101 or other pipeline candidates
- âš
Competitive advancements from other allogeneic cell therapy developers
- âš
Regulatory delays or unfavorable rulings for NK cell therapies
Unlock ARTV Red Flags & Risk Warnings
Create a free account to see the full analysis
ARTV Financial Health Metrics
Market Cap
$102.60M
ARTV Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding (if clinical validation and IP protection are successful)
Moat Sources
2 Identified
The moat's durability is currently dependent on successful clinical trials, which will validate the platform and attract further investment/partnerships. Strong patent protection around their specific NK cell lines and manufacturing will be key.
ARTV Competitive Moat Analysis
Sign up to see competitive advantages
ARTV Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated mid-March 2026)
- •Announcement of new financing round (critical, urgent)
- •Presentation of updated AB-101 Phase 1/2 clinical data
Medium-Term (6-18 months)
- •Expansion or new terms of collaboration with Merck
- •Initiation of additional clinical trials for pipeline candidates
- •Strategic partnership with a new large pharmaceutical company
Long-Term (18+ months)
- •Advancement of lead candidates into pivotal Phase 3 studies
- •Potential market approval and commercialization of first off-the-shelf NK cell therapy
- •Industry-wide adoption of allogeneic cell therapies
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
ARTV Bull Case: What Could Go Right
- ✓
Announcement of a substantial equity financing round or non-dilutive partnership funding (positive)
- ✓
Positive Phase 1/2 clinical data updates for AB-101 (positive)
- ✓
Continued depletion of cash reserves without financing (negative, increases shutdown risk)
- ✓
Any indications of significant trial delays or safety concerns (negative)
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
